Ferrari, Guido
- Duke University · Surgery (NIH department code)
- Duke University · Internal Medicine (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #511
- Top 5% Funded
- Mentor
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2001 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Surgery
- Internal Medicine
NIH Funding · FY2023
Linked Award Amount
$6.4M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#511
By linked amount among FY2023 PIs
Earliest Year Loaded
2001
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Ferrari, Guido as a PI. Multi-PI records show the full award amount for context.
- 5UM1AI169633-02UM1Contact PISOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimensDuke University · Surgery (NIH department code)$5.9Maward amount
- 5T32AI007392-34T32Contact PIInterdisciplinary Research Training Program in AIDSDuke University · Internal Medicine (NIH department code)$496.7Kaward amount
Award organization
Organizations that administered FY2023 awards listing Ferrari, Guido as a PI.
FY2023 award administered by Duke University (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2001First NIH AwardDuke University
- 2002$500K Cumulative Funding
- 2003$1M Cumulative Funding
- 2020$2M Cumulative Funding
- 2022$5M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #518
- 2022Entered Top 25% NationallyRanked #518
- 2022Entered Top 10% NationallyRanked #518
- 2022Entered Top 5% NationallyRanked #518
- 2023$10M Cumulative Funding